Clascoterone for Hair Loss: How the Topical Anti-Androgen Works

Clascoterone is a topical anti-androgen that blocks androgen receptors directly at the follicle without entering systemic circulation in meaningful amounts. It is already FDA-approved for acne under the brand name Winlevi, and its investigational formulation for androgenetic alopecia (AGA), known as Breezula, has now completed two Phase 3 trials. The appeal is straightforward: local androgen blockade without the sexual side effects that keep many men from starting treatment. BaldingAI lets you capture baseline density scans before trialing any new treatment, so you have objective data to compare against rather than relying on mirror impressions weeks later.

What is clascoterone and how does it work?

Clascoterone (cortexolone 17-alpha-propionate) is a steroidal anti-androgen designed for topical application. Its mechanism is competitive antagonism at the androgen receptor (AR). In practical terms, clascoterone binds to the same receptor that dihydrotestosterone (DHT) uses to trigger follicular miniaturization, but it does not activate the receptor. It occupies the binding site and prevents DHT from docking, which interrupts the downstream signaling cascade that shortens anagen and shrinks the follicle.

This is a fundamentally different approach from finasteride and dutasteride. Those drugs are 5-alpha reductase inhibitors: they reduce the conversion of testosterone to DHT throughout the body, lowering serum DHT levels by roughly 70% (finasteride) or 90% (dutasteride). Clascoterone does not touch DHT production at all. It lets your body produce normal amounts of DHT but blocks that DHT from activating receptors in the scalp. The distinction matters because the systemic effects of DHT suppression are what produce the side-effect profile that concerns many patients.

Once applied to the scalp, clascoterone is rapidly metabolized into cortexolone, a compound with minimal androgenic or anti-androgenic activity. This rapid local metabolism is what limits systemic exposure. Pharmacokinetic studies have shown that even at the higher concentrations used for AGA, plasma levels of clascoterone remain well below thresholds associated with systemic anti-androgenic effects.

How it differs from topical finasteride

Topical finasteride has gained traction as a way to reduce scalp DHT while minimizing systemic absorption compared to oral finasteride. But topical finasteride still inhibits 5-alpha reductase, and studies show it does reduce serum DHT to some degree, typically by 25 to 35% depending on formulation and dose (Piraccini et al., 2022). The reduction is smaller than the oral form, but it is not zero.

Clascoterone operates through a completely separate pathway. Because it is a receptor blocker rather than an enzyme inhibitor, it does not reduce circulating DHT at all. A 2020 pharmacokinetic analysis published in the Journal of Drugs in Dermatology confirmed that clascoterone 1% cream (the acne formulation) did not produce statistically significant changes in serum testosterone, DHT, or cortisol levels versus placebo. The AGA formulation uses a higher concentration, but the rapid local metabolism to cortexolone still limits systemic activity.

For men who experienced sexual side effects on finasteride or who are unwilling to risk them, this pharmacological profile is what makes clascoterone compelling. It is not simply another topical version of the same drug class. It is a different mechanism entirely.

Phase 3 trial results for androgenetic alopecia

Two identically designed Phase 3 trials, Scalp 1 (NCT05910450) and Scalp 2 (NCT05914805), tested clascoterone 5% solution in male androgenetic alopecia. Both are registered as randomised, double-blind, vehicle-controlled studies run in the United States and Europe, and both are recorded on ClinicalTrials.gov as completed.

Cosmo Pharmaceuticals, which now develops the compound, announced topline results on 3 December 2025. It reported that 1,465 patients were randomised across the two studies and that both met their target area hair count endpoint, one at a 539% relative improvement versus placebo and the other at 168%. Those are relative figures against a placebo arm, not absolute hair counts, so they are best read as evidence that the endpoint was met rather than as an effect size you can expect on your own scalp.

Twelve-month data followed on 15 April 2026. Cosmo reported that clascoterone kept a safety and tolerability profile comparable to vehicle with no significant systemic hormonal effects, and that patients who stayed on it for the full twelve months had a statistically significant 2.39x improvement in target area hair count over patients who took it for six months and were then switched to vehicle.

It is worth keeping the limits of these numbers in view. They come from the developer's own press releases; as of this update the full Phase 3 results have not been published in a peer-reviewed journal, so the detail that would let an outside reader judge them is not yet available.

Current FDA and regulatory status

Clascoterone 1% cream (Winlevi) received FDA approval in August 2020 for the treatment of acne vulgaris in patients 12 years and older. It was the first new acne drug mechanism approved in roughly 40 years. The approval was based on two Phase III trials (CB-03-01/25 and CB-03-01/26) that demonstrated superiority over vehicle in reducing inflammatory and non-inflammatory acne lesions.

The AGA formulation (clascoterone 5% solution) does not have FDA approval. It is an investigational product. Cosmo said on 15 April 2026 that a US FDA filing is planned for early 2027, with a European application in preparation alongside it. Some dermatologists have explored off-label use of Winlevi (the 1% acne cream) on the scalp, but the lower concentration and cream vehicle were not designed for scalp application, and the Phase 3 efficacy data is specific to the 5% solution.

If you are considering clascoterone for hair loss, it is worth having a direct conversation with a dermatologist about the current status. Using an acne cream off-label on the scalp is not the same as using the purpose-built AGA formulation, and you should not assume the same results.

Who might benefit most from clascoterone?

The patient profile most likely to benefit from clascoterone for AGA, if and when it reaches market, falls into a few categories. First: men who have discontinued finasteride due to side effects or who are unwilling to start it. For this group, clascoterone would represent the first topical anti-androgen with a plausible side-effect advantage. Second: men who are already on minoxidil and want to add an anti-androgen component without the systemic DHT suppression of finasteride. Third: women with androgenetic alopecia, for whom systemic anti-androgens like spironolactone carry their own side-effect considerations and for whom finasteride is not FDA-approved.

It is less likely to replace finasteride for men who tolerate it well, because finasteride has a far deeper evidence base and a known efficacy ceiling. The role of clascoterone, at least initially, is more likely as an alternative for the finasteride-intolerant or finasteride-averse population.

How to track response if you trial clascoterone

Any new treatment for androgenetic alopecia requires a structured tracking protocol to determine whether it is working. This is especially true for a novel agent like clascoterone, where personal response data is valuable because the published dataset is still small.

Before your first application, take a full set of baseline scans covering your hairline, temples, crown, and part line. Use consistent lighting, angle, and hair state. BaldingAI standardizes these variables across scans so that changes in density scores reflect actual follicular changes rather than photographic noise. Scan every one to two weeks and log the date you started treatment, application frequency, and any co-treatments you are using.

Based on the Phase 3 timeline, plan to evaluate at 6 months minimum. Follicular miniaturization reversal is a slow biological process. Early responders may see density shifts at 3 to 4 months, but drawing conclusions before 6 months risks false negatives. If your density trend is flat or declining at 12 months, that is a clear signal to reassess with your dermatologist.

The bottom line

Clascoterone represents a genuinely new mechanism for treating androgenetic alopecia: local androgen receptor blockade without systemic DHT suppression. Both Phase 3 trials met their endpoint, the reported safety profile is clean, and the pharmacological rationale is sound. But it is not approved for hair loss, the full results are not yet published, and the AGA-specific formulation is not commercially available.

If the planned early-2027 filing leads to approval, clascoterone will likely fill an important gap for patients who cannot or will not tolerate finasteride. Until then, the responsible approach is to stay informed, discuss it with a board-certified dermatologist, and track whatever treatment you do use with enough rigor to know whether it is actually working.

Sources: Hebert et al. 2020, Journal of Drugs in Dermatology , Piraccini et al. 2022, Dermatologic Therapy, Cosmo Pharmaceuticals, Phase III topline results, 3 December 2025, Cosmo Pharmaceuticals, Phase III 12-month data, 15 April 2026, ClinicalTrials.gov NCT05910450 and NCT05914805.